Amneal Shares up 7.8% Despite GuruFocus Overvaluation Warning
AMRX hit $20.16 on Sept 21, rising 60% YTD, yet GuruFocus flags a 146% premium over intrinsic value and cites $9.8M in insider sales.
Key points
- AMRX shares rose 7.8% to $20.16 on Sept 21, marking a 60% YTD gain and 105.5% one-year increase.
- GuruFocus values AMRX at $8.19, indicating the current price is 146.2% above intrinsic value and significantly overvalued.
- Insiders sold $9.8 million in shares over the past year with no buying, while only one guru holds the stock.
Amneal Pharmaceuticals (AMRX) shares climbed 7.8% to $20.16 on September 21, 2026, extending a year-to-date gain of 60.0% and a one-year increase of 105.5%. The stock now sits near the top of its 52-week range, which spans from $9.49 to $21.18, reflecting a sharp re-rating by the market.
Despite this price action, GuruFocus analysis indicates the stock is trading at a significant premium to its estimated intrinsic value. The divergence between the market price and fundamental metrics raises questions about the sustainability of the recent rally.
Valuation metrics signal overpricing
GuruFocus assigns a GF Value™ estimate of $8.19 to AMRX, placing the current $20.16 share price 146.2% above this benchmark. This gap leads the platform to categorize the stock as "Significantly Overvalued," suggesting that the current market price does not reflect the underlying financial metrics or future growth prospects.
While the trailing twelve-month P/E ratio stands at 42.1x, which is 35% below the five-year median of 64.4x, the forward P/E of 16.8x offers limited comfort. The GF Score™ of 59/100 highlights a valuation sub-score of just 1/10, indicating poor pricing relative to fundamentals despite average profitability and growth scores of 6/10.
Insider sales signal caution
Activity by company insiders and institutional investors suggests a bearish outlook. Over the past 12 months, insiders sold $9.8 million worth of shares without recording any buying activity. This one-way flow of transactions indicates that those closest to the business are reducing their exposure.
Institutional sentiment appears similarly cautious. Only one guru currently holds AMRX, with no recent additions to positions and three trims in recent quarters. This lack of institutional accumulation contrasts with the retail-driven price surge, highlighting a potential disconnect between market price and professional investor conviction.
Financial strength remains moderate
The company's financial profile shows mixed signals. A financial strength score of 4/10 suggests Amneal has some stability but may lack the robustness to weather significant downturns. Profitability and growth both score 6/10, indicating decent performance, but the momentum score of 3/10 reflects the difficulty in sustaining recent gains against valuation headwinds.
Investors face a scenario where the stock price has decoupled from intrinsic value metrics. The combination of high valuation multiples, insider selling, and moderate financial strength creates a risk profile that demands caution, as the market may eventually adjust its perception of the company's worth.
